subject: Orexigen Therapeutics Inc: Corporate And Strategic Assessment Report Company Strategy, Swot [print this page] Introduction Introduction
Orexigen Therapeutics (Orexigen) focuses on the development and commercialization of therapeutics for central nervous system (CNS) disorders with initial focus on obesity. The company leverages its proprietary low-throughput screening model technology to screen drugs and combine approved generic drugs to create new therapeutics for CNS to improve energy expenditure.
Scope
*Contains corporate strategy, value chain presence and SWOT Analysis
*Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
*Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Orexigen's innovative low-throughout screening model technology used in developing compositions for Contrave and Empatic was licensed from Oregon Health & Science University (OHSU), in 2003. Naltrexone and bupropion, which are the basic compounds for Contrave, are licensed from Dr. Lee G Dante, in 2004.
Orexigen derived revenues in 2006 from Cypress Biosciences for granting sublicense to Orexigen's licensed technology. Revenues decreased from $0.3 million in 2005 to $0.09 in 2006 primarily due to the expiry of the collaborative agreement with Eli Lilly in 2005.
Orexigen does not forecast any revenues during the period 2006-2010 as the company has no products to be launched and as well as any licensing agreement during 2006-2010. The only agreement for sublicensing technology to Cypress Biosciences (Cypress), for Obstructive Sleep Apnea treatment, was discontinued in 2006.
Reasons to Purchase
*Access all the important information and analysis on the company in a single report
*Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
*Gain access to company's adjusted five year financial data along with key ratios and market capitalization
